Treatment schema. Patients who relapsed after MHC-matched allogeneic HCT and elected to receive chemotherapy and T-cell therapy first underwent withdrawal of immunosuppression, followed sequentially by appropriate salvage chemotherapy, adoptive T-cell therapy with CD8⁺ mHAg-specific CTL clones, and a 14-day course of low-dose IL-2.